Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 38

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 38
---
 |   623,002 |
| Charlotte McKee, M.D.                                     |     |      | 2024 |     |            | 449,946 |     |        |   635,318 |     |                | 197,976 |     |           | 1,283,240 |
| Chief Medical Officer                                     |     |      | 2023 |     |            | 432,640 |     |        |         — |     |                | 190,362 |     |           |   623,002 |

| (1) | For fiscal year 2024, the amounts reported represent the aggregate grant date fair value of stock option awards granted to our NEOs during such fiscal year, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our 2024 Annual Report under heading “Critical Accounting Estimates.” Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. The amounts reported in this column reflect the accounting cost for the stock option award and do not correspond to the actual economic value that may be received by our NEOs upon the vesting of the awards or any sale of the underlying securities. |

| (2) | Amounts reflect bonuses earned based on our achievement of specified performance metrics for the applicable fiscal year pursuant to our non-equity incentive plan. |

Narrative Disclosure to Summary Compensation Table Overview Our executive compensation program is designed to attract, motivate and retain key employees who we believe best represent our company values and can make significant contributions towards achieving our business purpose. Our program is structured to incentivize our executive team based on the achievement of key performance goals, and to align their interests with those of our stockholders. Under this program, our NEOs’ compensation is based on the achievement of key strategic and business goals that were developed based on our mission. The program consists of a combination of base salary, an annual cash bonus, long-term equity incentive compensation and other employee benefits generally available to our employees and is designed to align our 27

executive compensation program with the interests of our stockholders by reflecting a pay-for-performance philosophy that supports our business strategy. At the same time, the Board believes that the program does not encourage excessive risk-taking by management.

Our compensation committee is generally responsible for determining the compensation of our executive officers. In setting executive base salaries and